Group 1 - Novo Nordisk's stock price fell over 21% on July 29, with its weight loss drug Wegovy facing weak growth expectations in the U.S. market [3][4] - The company revised its full-year sales and profit guidance downwards, projecting sales growth of 8% to 14%, compared to the previous target of 13% to 21% [4] - Novo Nordisk's operating profit is now expected to grow by 10% to 16%, down from earlier expectations of 21% and 24% [4] Group 2 - The decline in expectations is attributed to competition from cheaper generic versions of Wegovy and overall market growth being lower than anticipated [4] - Analysts are beginning to question the short-term and long-term outlook for the company in the obesity treatment sector, which has seen inflated expectations [4] - Novo Nordisk announced the appointment of Maziar Mike Doustdar as the new CEO, replacing Lars Fruergaard Jorgensen, who was unexpectedly removed in May [5]

Group 1: Market Overview - On July 29, U.S. stock indices opened slightly higher, with the Dow Jones up 0.02%, Nasdaq up 0.5%, and S&P 500 up 0.22% [1][2] - European stock markets showed broad gains, with the FTSE 100 up 0.74%, CAC 40 up 1.3%, DAX up 1.32%, and FTSE MIB up 1.53% [2][3] Group 2: Company Performance - Novo Nordisk's stock plummeted over 21% after the company lowered its 2025 outlook, citing weak growth expectations for its weight loss drug Wegovy in the U.S. market [5][6] - Eli Lilly's stock also fell nearly 6% amid the competitive landscape [6] - Novo Nordisk revised its sales growth forecast for the year to 8%-14%, down from the previous 13%-21%, and its operating profit growth forecast to 10%-16%, down from 21%-24% [9] - The company attributed the lowered expectations to competition from cheaper generic versions of Wegovy and overall market growth being below expectations [9] - Novo Nordisk announced that Maziar Mike Doustdar will replace Lars Fruergaard Jorgensen as CEO, following a series of setbacks [9]

Group 1: Company Performance - Novo Nordisk's stock price opened significantly lower, dropping over 21% as of the report time, while Eli Lilly's stock fell nearly 6% [6][8]. - Novo Nordisk revised its full-year sales and profit guidance downwards, citing weak growth expectations for its flagship weight loss drug Wegovy in the critical U.S. market [9]. Group 2: Financial Forecasts - The company now expects sales growth (at constant exchange rates) to be between 8% and 14%, down from a previous target of 13% to 21%. Operating profit growth is now projected at 10% to 16%, compared to earlier expectations of 21% and 24% [9]. - The downward revision is attributed to competition faced by Wegovy and its sister diabetes drug Ozempic, as well as the presence of cheaper generic versions of Wegovy in the U.S. market [9]. Group 3: Management Changes - Novo Nordisk announced that Maziar Mike Doustdar will replace Lars Fruergaard Jorgensen as the new CEO, following Jorgensen's unexpected removal in May [9].

每经AI快讯，7月29日，美股医疗保健板块集体下挫。诺和诺德跌超19%，默沙东跌超8%，礼来跌超 5%。 ...

礼来(LLY.N)股价下跌5.8%，此前竞争对手诺和诺德下调了2025年的销售增长和运营利润预期。 ...

格隆汇7月29日｜诺和诺德(NVO.US)盘前跳水，现跌逾13%；礼来盘前亦跌逾2%。消息面上，诺和诺 德下调2025财年销售预期，下调与美国减肥药Wegovy销售下降有关。销售前景反映了复合GLP-1的持 续使用，市场扩张放缓，竞争加剧。此外，2025年前六个月，诺和诺德的销售额增长18%，营业利润增 长29%。(格隆汇) ...

（文章来源：每日经济新闻） 每经AI快讯，7月29日，礼来美股盘前下跌2.2%。 ...

智通财经7月29日电，礼来美股盘前下跌2.2%，受诺和诺德大跌影响。 ...

Policy Developments - Shanghai Municipal Drug Administration issued the "Priority Approval Procedure for Class II Medical Devices," allowing certain medical devices to enter a priority approval process based on specific criteria, including those related to rare diseases and urgent clinical needs [2]. Drug and Device Approvals - Eli Lilly's GLP-1 drug Tirzepatide (brand name: Mounjaro) received approval for a new indication in China, allowing its use in conjunction with insulin for adult Type 2 diabetes patients, potentially boosting its revenue [4]. - Dongcheng Pharmaceutical obtained a radioactive drug production license, although it is not expected to significantly impact current performance until further approvals are secured [5]. - Shanghai Pharmaceuticals' salbutamol injection passed the consistency evaluation for generic drugs, indicating its quality and efficacy for treating respiratory diseases [6]. Financial Reports - Qizheng Tibetan Medicine reported a 16.36% increase in total revenue to 1.175 billion yuan and a 9.94% rise in net profit to 358 million yuan for the first half of 2025 [8]. Capital Market Developments - Laimei Pharmaceutical announced a change in its indirect controlling shareholder structure, with Guangxi State-owned Assets Supervision and Administration Commission planning to transfer 33% of Guangtou Group's shares to Guangxi State Control Group without affecting the company's operations [10]. - Hengrui Medicine entered a licensing agreement with GSK for global exclusive rights to the HRS-9821 project and up to 11 additional projects, with potential milestone payments totaling approximately $12 billion [12]. Industry Highlights - Yanshan Technology's subsidiary made breakthroughs in brain-computer interface technology, aiming to enhance communication for patients with speech impairments due to neurological conditions [14]. - The Guangdong Institute of Intelligent Science and Technology announced the launch of the world's first multi-modal dream brain-computer interface device, designed to improve sleep quality and manage health [15]. - Bristol-Myers Squibb received approval for China's first dual immunotherapy for first-line treatment of non-small cell lung cancer, marking a significant advancement in cancer treatment options [16]. Market Movements - Shanghai Zhangjiang Group reduced its stake in MicroPort Medical, selling 37 million shares at approximately HKD 9.84 per share, totaling around HKD 364 million [18].

Group 1 - Heng Rui Medicine signed an agreement with GSK for the global exclusive rights of the HRS-9821 project and up to 11 additional projects, potentially worth around $12 billion [1] - GSK will pay Heng Rui a $500 million upfront payment, with additional milestone payments based on successful development, registration, and sales [1] - Heng Rui's stock surged, closing at 62.04 CNY per share, with a market capitalization exceeding 400 billion CNY, indicating strong market sentiment towards the innovative drug sector [1] Group 2 - Eli Lilly's drug, Tirzepatide injection, received approval from China's NMPA for a new indication to improve blood sugar control in adult patients with type 2 diabetes [2] - The new indication allows for the combination of Tirzepatide with insulin, providing a better treatment option for patients who do not respond well to insulin alone [2] - This approval helps Eli Lilly strengthen its market share in the diabetes treatment sector in China [2] Group 3 - Hotgen Biotech developed an antibody test kit for Chikungunya virus, enabling rapid qualitative detection within 15 minutes [3] - The test kit is designed for use in suspected case screening and large-scale monitoring, although it has not yet received regulatory approval for medical use [3] - The stock price of Hotgen Biotech increased by 6.88%, reflecting market response to the potential impact of the test kit amid a Chikungunya outbreak [4] Group 4 - WuXi AppTec reported a net profit of 8.561 billion CNY for the first half of 2025, a year-on-year increase of 101.92% [5] - The company achieved a revenue of 20.799 billion CNY, up 20.64% year-on-year, and plans to distribute a cash dividend of 3.5 CNY per 10 shares [5] - WuXi AppTec raised its revenue guidance for 2025, expecting a growth rate of 13% to 17% [5][6]